FDA letter delays OK for Amgen bone drug Prolia
Amgen Inc. said Monday the Food and Drug Administration wants more information about its osteoporosis treatment Prolia before granting marketing approval. It delays a drug seen as a potential blockbuster for the company. In a letter, the FDA said it wants to ...